Synthesis, antiproliferative and pro-apoptotic activity of 2-phenylindoles
Patrick M Kelly1, Sandra A Bright2, Darren Fayne2
1School of Pharmacy & Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland.
Abstract:
Breast cancer is the second most common cancer worldwide after lung cancer with the vast majority of early stage breast cancers being hormone-dependent. One of the major therapeutic advances in the clinical treatment of breast cancer has been the introduction of selective estrogen receptor modulators (SERMs). We describe the design and synthesis of novel SERM type ligands based on the 2-arylindole scaffold to selectively target the estrogen receptor in hormone dependent breast cancers. Some of these novel compounds are designed as bisindole type structures, while others are conjugated to a cytotoxic agent based on combretastatin A4 (CA4) which is a potent inhibitor of tubulin polymerisation. The indole compounds synthesised within this project such as 31 and 86 demonstrate estrogen receptor (ER) binding and strong antiproliferative activity in the ER positive MCF-7 breast cancer cell line with IC50 values of 2.71μM and 1.86μM respectively. These active compounds induce apoptotic activity in MCF-7 cells with minimal effects on normal peripheral blood cells. Their strong anti-cancer effect is likely mediated by the presence of two ER binding ligands for 31 and an ER binding ligand combined with a cytotoxic agent for 86.
Insights
Novel selective estrogen receptor modulators (SERMs) based on 2-arylindole scaffolds show potent anti-cancer activity against hormone-dependent breast cancer cells. These compounds induce apoptosis with minimal impact on normal cells, offering a promising therapeutic avenue.
Area of Science:
- Medicinal Chemistry
- Oncology
- Molecular Pharmacology
Background:
- Breast cancer is a leading global cancer, with many early-stage cases being hormone-dependent.
- Selective Estrogen Receptor Modulators (SERMs) represent a key therapeutic advancement for breast cancer treatment.
Purpose of the Study:
- To design and synthesize novel SERM-type ligands utilizing the 2-arylindole scaffold.
- To selectively target the estrogen receptor (ER) in hormone-dependent breast cancers.
Main Methods:
- Synthesis of novel 2-arylindole derivatives, including bisindole structures and conjugates with combretastatin A4 (CA4).
- Evaluation of estrogen receptor binding affinity and antiproliferative activity in ER-positive MCF-7 breast cancer cells.
- Assessment of apoptotic activity and effects on normal peripheral blood cells.
Main Results:
- Indole compounds 31 and 86 exhibited significant ER binding and potent antiproliferative effects in MCF-7 cells (IC50 values of 2.71μM and 1.86μM, respectively).
- These active compounds demonstrated induction of apoptosis in MCF-7 cells.
- Minimal toxicity was observed in normal peripheral blood cells.
Conclusions:
- Novel 2-arylindole compounds, including bisindoles and CA4 conjugates, show promise as targeted therapies for hormone-dependent breast cancer.
- Compound 31's efficacy may stem from dual ER binding, while compound 86 combines ER binding with cytotoxic tubulin inhibition.
More Related Videos
Related Concept Videos
The Intrinsic Apoptotic Pathway
Abnormal Proliferation
Oxidation of Phenols to Quinones
o-hydroxy phenols are oxidized to o-quinones and p-hydroxy phenols to p-quinones. Such redox reactions involve the transfer of two electrons and two protons. The reversible redox...
ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3
Inhibition of Cdk Activity
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...


